Clariane (CLARI) 주식 개요
클라리네 SE는 프랑스, 독일, 베네룩스, 이탈리아, 스페인, 영국에서 요양원, 의료 시설 및 서비스, 공유 생활 솔루션을 제공하고 있습니다. 자세히 보기
CLARI Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Clariane SE 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €4.03 |
| 52주 최고가 | €4.92 |
| 52주 최저가 | €3.27 |
| 베타 | 0.82 |
| 1개월 변동 | 1.56% |
| 3개월 변동 | -1.27% |
| 1년 변동 | -15.56% |
| 3년 변동 | -32.30% |
| 5년 변동 | -87.48% |
| IPO 이후 변동 | -88.90% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 02
CLARI: Hybrid Notes Refinancing Will Test Support For Elevated Future P/E
Analysts have lifted their fair value estimate for Clariane from €3.10 to €4.70, citing updated assumptions on discount rates, modestly higher revenue growth and profit margins, and a revised forward P/E framework. Analyst Commentary While the recent fair value uplift signals a more constructive stance on Clariane, some of the broader Street commentary on comparable stocks highlights why a portion of the market is still cautious around execution and valuation risk for companies in adjacent segments.
내러티브 업데이트 • Jun 18
CLARI: Higher P/E Assumptions Will Drive More Constructive Share Price Outlook
For Clariane, the analyst price target has been adjusted from €4.53 to €4.66 as analysts factor in updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research on Clariane reflects a mix of optimism and caution, with analysts focusing on how the company can execute against its assumptions on valuation metrics, margins, and growth.
내러티브 업데이트 • Jun 03
CLARI: Brand Strength And Margin Focus Will Support Future Re Rating
Analysts have adjusted their price target on Clariane to €5.10. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E, and broadly aligns with a more constructive stance on the stock in recent research.Recent updates
내러티브 업데이트 • Jul 02
CLARI: Hybrid Notes Refinancing Will Test Support For Elevated Future P/E
Analysts have lifted their fair value estimate for Clariane from €3.10 to €4.70, citing updated assumptions on discount rates, modestly higher revenue growth and profit margins, and a revised forward P/E framework. Analyst Commentary While the recent fair value uplift signals a more constructive stance on Clariane, some of the broader Street commentary on comparable stocks highlights why a portion of the market is still cautious around execution and valuation risk for companies in adjacent segments.내러티브 업데이트 • Jun 18
CLARI: Higher P/E Assumptions Will Drive More Constructive Share Price Outlook
For Clariane, the analyst price target has been adjusted from €4.53 to €4.66 as analysts factor in updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research on Clariane reflects a mix of optimism and caution, with analysts focusing on how the company can execute against its assumptions on valuation metrics, margins, and growth.내러티브 업데이트 • Jun 03
CLARI: Brand Strength And Margin Focus Will Support Future Re Rating
Analysts have adjusted their price target on Clariane to €5.10. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E, and broadly aligns with a more constructive stance on the stock in recent research.내러티브 업데이트 • May 01
CLARI: Softer Demand And Margin Risks Will Pressure Elevated Future P/E
Analysts have maintained their fair value estimate for Clariane at €3.10, while refining assumptions around the discount rate, revenue growth and margins after recent Street research reduced price targets due to softer near-term demand and margin pressure, yet still emphasized the company’s longer-term brand strength. Analyst Commentary Recent Street research around Clarus points to a more cautious tone that readers may want to keep in mind when comparing fair value estimates to current trading levels.내러티브 업데이트 • Apr 17
CLARI: Brand Strength And Margin Efficiency Will Support Future Upside Potential
Analysts have trimmed their price target on Clariane by €1, reflecting recent Street research that points to softer near term expectations while still highlighting the company’s brand assets and potential for margin improvement. Analyst Commentary Recent Street research on related names points to a mixed setup, with price targets trimmed following Q4 results that fell short of expectations and highlighted softer demand and margin pressure.내러티브 업데이트 • Apr 02
CLARI: Higher Margin Focus And Steady Risk Profile Will Support Upside
Analysts have trimmed their fair value estimate for Clariane to €5.10 from €5.20, reflecting slightly softer assumed revenue growth, a modestly higher profit margin outlook, and a lower future P/E multiple. Analyst Commentary Bullish analysts continue to see room for value in Clariane despite the recent trim to fair value, with attention on execution against revenue and margin assumptions rather than broad multiple expansion.내러티브 업데이트 • Mar 19
CLARI: Softer Revenue And Margin Pressure Will Strain Elevated Future P/E
Analysts have lowered their price target on Clariane from €4.00 to €3.10, citing softer revenue growth assumptions, lower expected profit margins, and a higher discount rate. Together, these factors point to a richer future P/E multiple of about 93x.내러티브 업데이트 • Mar 05
CLARI: Lower Discount Rate And Margin Outlook Will Support Bullish Momentum
Analysts have nudged their price target on Clariane slightly higher to €4.53 from €4.49, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. Valuation Changes Fair Value: updated slightly higher from €4.49 to €4.53.내러티브 업데이트 • Feb 18
CLARI: Stable Assumptions And Lower P/E Multiple Will Support Bullish Momentum
Analysts have trimmed their 12 month price target for Clariane to €4.49. This reflects slightly adjusted assumptions on revenue growth, profit margins and future P/E expectations, while keeping the overall valuation framework unchanged.내러티브 업데이트 • Feb 03
CLARI: Stable Fair Value And Slight Margin Improvement Will Support Upside
Analysts have trimmed their price target on Clariane to €5.20, citing only slight adjustments to expected revenue growth, profit margins, and future P/E assumptions. Their overall valuation framework remains broadly unchanged.내러티브 업데이트 • Jan 20
CLARI: Earnings Guidance Confirmation Will Support Bullish Momentum Through 2025 Targets
Analysts have trimmed their price target for Clariane to reflect a fair value move from €4.72 to about €4.49, citing slightly adjusted revenue growth assumptions, a marginally higher profit margin outlook, and a lower future P/E multiple. What's in the News Clariane confirmed its group earnings guidance for 2025, repeating its targets rather than updating them (Key Developments).내러티브 업데이트 • Jan 06
CLARI: Confirmed 2025 Guidance And Higher Future P/E Will Support Upside
Analysts have adjusted their price target on Clariane to reflect an unchanged fair value of €5.20, revised revenue growth and profit margin assumptions, and a higher future P/E of 16.77x. What's in the News Clariane SE confirmed its group earnings guidance for 2025, giving investors a clearer view of management expectations for the year (Key Developments).내러티브 업데이트 • Dec 20
CLARI Will Benefit From Confirmed 2025 Guidance And Revenue Visibility
Narrative Update on Clariane Analysts have trimmed their price target on Clariane from €6.80 to €5.20, citing lower expected revenue growth, compressed profit margins, and a higher implied future valuation multiple that together point to a more challenging earnings outlook. What's in the News Clariane SE confirmed its group earnings guidance for 2025, maintaining an organic revenue growth target of around 5 percent (company guidance) The reaffirmed 2025 target indicates that management remains confident in demand resilience and the companys ability to execute its strategic plan despite margin pressures (company guidance) Stable forward guidance provides greater visibility for investors, which may reduce uncertainty around Clarianes medium term growth trajectory (company guidance) Valuation Changes Fair Value: reduced significantly from €6.80 to €5.20, implying a more cautious assessment of upside potential.내러티브 업데이트 • Dec 06
CLARI: Earnings Guidance Confirmation Will Support Bullish Momentum Into 2025
Narrative Update on Clariane Analysts have marginally increased their price target on Clariane to approximately €4.72, reflecting slightly stronger expectations for revenue growth and profit margins, while maintaining a broadly unchanged valuation framework. What's in the News Clariane SE confirmed its group earnings guidance for 2025, reiterating confidence in its financial trajectory despite sector headwinds (company guidance).내러티브 업데이트 • Nov 22
CLARI: Earnings Guidance Confirmation Will Support Bullish Momentum Into 2025
Clariane’s analyst price target has been revised downward from €5.16 to €4.72, as analysts cite a combination of slower revenue growth and weaker profit margins to support this updated outlook. What's in the News Clariane SE has confirmed its group earnings guidance for the year 2025 (Key Developments) The company reiterated its organic revenue growth target of approximately 5% for 2025 (Key Developments) Valuation Changes The consensus analyst price target has fallen from €5.16 to €4.72, reflecting a revised outlook.분석 기사 • Nov 08
The Price Is Right For Clariane SE (EPA:CLARI) Even After Diving 26%
The Clariane SE ( EPA:CLARI ) share price has fared very poorly over the last month, falling by a substantial 26...분석 기사 • Oct 12
These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...내러티브 업데이트 • Aug 07
Aging Europe And Digital Adoption Will Advance Long Term Care
Clariane’s fair value has been revised upward as improving net profit margin outweighed the impact of a higher discount rate, resulting in the consensus price target rising from €4.91 to €5.16. What's in the News Clariane SE expects organic sales growth of around 5% for 2025, supported by strong momentum in France and Germany, with ramp-up contributions in the Netherlands and Spain.분석 기사 • Jun 22
Revenues Tell The Story For Clariane SE (EPA:CLARI)
There wouldn't be many who think Clariane SE's ( EPA:CLARI ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...새로운 내러티브 • May 05
Refinancing And French Pricing Will Pressure Margins But Build Resilience
Ongoing disposal plan and deleveraging efforts may limit opportunistic growth and reduce future revenue streams.분석 기사 • Apr 03
Does Clariane (EPA:CLARI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Mar 03
Why Investors Shouldn't Be Surprised By Clariane SE's (EPA:CLARI) 70% Share Price Surge
Despite an already strong run, Clariane SE ( EPA:CLARI ) shares have been powering on, with a gain of 70% in the last...분석 기사 • Dec 28
Clariane (EPA:CLARI) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Nov 05
Revenues Tell The Story For Clariane SE (EPA:CLARI) As Its Stock Soars 26%
Clariane SE ( EPA:CLARI ) shareholders would be excited to see that the share price has had a great month, posting a...분석 기사 • Sep 13
Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Aug 06
Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Clariane SE ( EPA:CLARI ) share price has dived 26% in the last thirty days...분석 기사 • Jun 04
Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year
Key Insights Clariane to hold its Annual General Meeting on 10th of June Salary of €520.0k is part of CEO Sophie...분석 기사 • May 22
Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate
Key Insights Clariane's estimated fair value is €7.05 based on Dividend Discount Model Current share price of €4.75...분석 기사 • May 22
Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher
The Clariane SE ( EPA:CLARI ) share price has done very well over the last month, posting an excellent gain of 187...분석 기사 • Apr 28
Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Dec 06
Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?
Clariane SE ( EPA:CLARI ), might not be a large cap stock, but it received a lot of attention from a substantial price...분석 기사 • Oct 31
These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Sep 21
Calculating The Fair Value Of Clariane SE (EPA:CLARI)
Key Insights The projected fair value for Clariane is €6.91 based on Dividend Discount Model Current share price of...분석 기사 • Jul 29
What Is Clariane SE's (EPA:CLARI) Share Price Doing?
While Clariane SE ( EPA:CLARI ) might not be the most widely known stock at the moment, it saw a decent share price...분석 기사 • Apr 04
At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?
Korian ( EPA:KORI ), might not be a large cap stock, but it received a lot of attention from a substantial price...분석 기사 • Mar 16
These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...주주 수익률
| CLARI | FR Healthcare | FR 시장 | |
|---|---|---|---|
| 7D | -0.6% | -1.0% | -2.1% |
| 1Y | -15.6% | -5.6% | 1.8% |
수익률 대 산업: CLARI은 지난 1년 동안 -5.6%의 수익을 기록한 French Healthcare 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: CLARI은 지난 1년 동안 1.8%를 기록한 French 시장보다 저조한 성과를 냈습니다.
주가 변동성
| CLARI volatility | |
|---|---|
| CLARI Average Weekly Movement | 3.1% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.4% |
| 10% least volatile stocks in FR Market | 2.3% |
안정적인 주가: CLARI는 지난 3개월 동안 French 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: CLARI의 주간 변동성(3%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2001 | 70,685 | Sophie Boissard | www.clariane.com |
클라리네 SE는 프랑스, 독일, 베네룩스, 이탈리아, 스페인, 영국에서 요양원, 의료 시설 및 서비스, 공유 생활 솔루션을 제공하고 있습니다. 이 회사는 장기 요양원 및 단기 요양원을 운영합니다. 또한 진단 외래 프로그램, 의료 및 전체 입원 서비스, 당일 입원 및 상담으로 구성된 헬스케어 서비스를 제공하고 급성기 및 재활 치료 시설, 정신 건강 관리 클리닉, 병원 홈 케어 네트워크, 가정 커뮤니티 간호 시설을 운영합니다.
Clariane SE 기초 지표 요약
| CLARI 기초 통계 | |
|---|---|
| 시가총액 | €1.44b |
| 순이익 (TTM) | €12.57m |
| 매출 (TTM) | €5.35b |
114.3x
주가수익비율(P/E)0.3x
주가매출비율(P/S)CLARI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| CLARI 손익계산서 (TTM) | |
|---|---|
| 매출 | €5.35b |
| 매출원가 | €3.68b |
| 총이익 | €1.67b |
| 기타 비용 | €1.66b |
| 순이익 | €12.57m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.035 |
| 총이익률 | 31.28% |
| 순이익률 | 0.23% |
| 부채/자본 비율 | 113.2% |
CLARI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/20 09:15 |
| 종가 | 2026/08/20 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Clariane SE는 14명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Fraser Donlon | Berenberg |
| Aleksander Peterc | Bernstein |
| Laurent Gelebart | BNP Paribas |